Home Blog Page 766

Bybit CEO Ben Zhou on Trust, AI, and the New Financial Platform at Paris Blockchain Week 2026

DUBAI, United Arab Emirates, April 15, 2026 /PRNewswire/ — What will it take to build a financial system that billions of people can trust — and barely notice?

That question set the tone for a fireside chat titled “Trust, Technology, and Transformation: Building the New Financial Platform for a Tokenized Economy”, where Bybit Co-founder and CEO Ben Zhou took the stage at Paris Blockchain Week 2026 to outline a future where finance becomes more intelligent, more accessible, and ultimately, invisible.

Rather than focusing on price cycles or short-term trends, Zhou framed the industry’s next chapter as a fundamental redesign of financial infrastructure — one driven by the convergence of artificial intelligence, programmable assets, and regulatory clarity.

From Interfaces to Intelligence: The Rise of Agentic Finance

Zhou challenged the conventional idea of how users interact with financial platforms. In the future, he suggested, users may not interact with platforms at all.

“We’ve introduced AI agent accounts that allow clients to create sub-accounts for AI to interact, execute strategies, and access market data,” Zhou shared. “Agentic payments are becoming a major theme — and we’re just at the beginning.”

Instead of manually navigating markets, users can delegate tasks to AI agents — systems that interpret data, execute decisions, and optimize outcomes in real time. Today, these applications are largely focused on analytics and data access. Tomorrow, they may redefine execution itself.

The implication is profound: the interface disappears, and intelligence takes its place.

The Quiet Transformation of Finance

While much of the public narrative still centers on “crypto,” Zhou pointed to a quieter, more consequential shift already underway.

Traditional financial institutions are not entering the space through speculation — they are integrating blockchain as infrastructure. Stablecoins, in particular, are emerging as the bridge, enabling faster payments, more efficient settlement, and global liquidity access.

In many cases, Zhou noted, these institutions are building on crypto rails without embracing the label itself.

This signals a turning point: crypto is no longer an alternative system — it is becoming part of the foundation.

Trust Is the Real Product

For Zhou, the defining constraint — and opportunity — is not technology, but trust.

“The regulatory framework has become significantly clearer in recent years. Jurisdictions like the UAE are setting the pace by actively welcoming innovation and providing structured pathways for growth.”

From Europe’s structured approach to the evolving stance in the United States and the United Kingdom, regulatory clarity is no longer a barrier — it is becoming a catalyst.

As rules solidify, institutions follow. And as institutions enter, the system begins to mature.

A System That Works Without Being Seen

Zhou closed with a perspective that reframed the industry’s ultimate goal:

“This is not about replacing existing financial systems, but enhancing them. Our focus is on building infrastructure that makes financial services more accessible, efficient, and intuitive for users globally.”

The end state, he suggested, is not a world where users think about blockchain, wallets, or even platforms — but one where financial services simply work, seamlessly embedded into everyday life.

In that future, trust is built into the system, intelligence operates in the background, and technology fades from view.

Ben Zhou, Co-founder and CEO of Bybit, speaks with Brian McGleenon of BeInCrypto during a fireside chat at Paris Blockchain Week 2026 on April 15, 2026.
Ben Zhou, Co-founder and CEO of Bybit, speaks with Brian McGleenon of BeInCrypto during a fireside chat at Paris Blockchain Week 2026 on April 15, 2026.

#Bybit / #TheCryptoArk / #NewFinancialPlatform

About Bybit

Bybit is the world’s second-largest cryptocurrency exchange by trading volume, serving a global community of over 80 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.

For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
For updates, please follow: Bybit’s Communities and Social Media

 Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube

 

Artilux Announces Inception™: A Hybrid Optoelectronic Architecture for the Next-Generation AI Computing

HSINCHU, April 15, 2026 /PRNewswire/ — Artilux today announced Inception™, an AI computing paradigm shift from conventional digital electronics to novel hybrid optoelectronics, delivering orders-of-magnitude improvements in both power and area efficiencies without relying on advanced CMOS process nodes and active cooling.

Artilux Inception™- A hybrid optoelectronic architecture for the next-generation AI computing
Artilux Inception™- A hybrid optoelectronic architecture for the next-generation AI computing

As AI workloads continue to scale rapidly across cloud, edge, and on-device computing, traditional digital processors face increasing limitations in energy consumption, chip size, data movement, and thermal management. Artilux Inception™ addresses these challenges by rethinking the fundamental physics of computation, and combining the strengths of photonics and electronics into a unified system.

At the core of Artilux Inception™ is an original optoelectronics-enabled hybrid systolic array architecture compatible with existing CPU/GPU/TPU/LPU, enabling large-scale general matrix–matrix multiplication (GEMM) — the dominant workload in modern AI computing — with no data skew and negligible propagation delay.

The hybrid analog/digital nature of this architecture enables massive parallel dot-product computation in a single step using a dense 2D array of optoelectronic neurons (OENs): Each OEN consists of a light emitter (e.g., GaN micro-LED), a photodetector (e.g., GeSi pixel), and an in-pixel memory, where the inputs and weights for multiply-and-accumulate (MAC) operations are represented by modulating the light emitter and the photodetector, followed by local charge storage and programmable activation. These OENs eliminate the need for Arithmetic Logic Unit (ALUs) for GEMM, which are conventionally implemented by pipelined digital electronics.

In addition, inputs and weights accessed from the external memory are fully reused during computations, significantly reducing the memory bandwidth as well as the data movement energy, while enabling the high-speed dynamic weight update that is essential for transformer-based AI workloads.

Artilux Inception™ can be built using mature CMOS process nodes and integration technologies that are compatible with existing semiconductor manufacturing infrastructure. Thanks to the excellent power handling per area of the optoelectronic architecture, it requires no active cooling and therefore significantly alleviates the system deployment complexity and cost.

“AI scaling cannot rely solely on advanced process nodes,” said Neil Na, Co-founder and CTO of Artilux. “With Artilux Inception™, we introduce a new AI computing paradigm — one that is grounded in first-principle thinking, and enabled by seamless integration of photonic and electronic systems. This shall unlock the next phase of energy-efficient AI computing.”

The foundational optoelectronic architecture is described in the paper titled “Implementation of transformer-based LLMs with large-scale optoelectronic neurons on a CMOS compatible platform,” recently published in the journal of APL Machine Learning. The co-authors of the published paper include renowned silicon photonics experts, including Prof. Richard Soref and Dr. Haisheng Rong, further showcasing the scientific rigor and industry relevance of this approach.

Artilux also announced that its first-generation processing core based on Artilux Inception™ is now under development, marking a critical milestone toward commercialization and positioning the company at the forefront of the AI computing industry. Extending beyond the published research, this processing core is designed to deliver over 12,000 TOPS (INT8) with approximately 50 mW/mm² power density using a standard GHz clock rate. These figures of merit include system components such as drivers, DACs, ADCs, and peripheral interfaces, ensuring a realistic end-to-end performance for energy-critical applications such as AI inference computations, offering a scalable path forward for next-generation AI infrastructure.

About Artilux

Founded in 2014, Artilux has been at the forefront of a new era in semiconductor and photonic innovation, pioneering GeSi (germanium silicon) technology that bridges the gap between the electronic and photonic worlds. Building on a proven track record of photonic innovations that address the growing demand for high data throughput and low power consumption, Artilux’s dedicated team continuously pushes the boundaries of technology — transforming fundamental scientific breakthroughs into real-world solutions spanning communications, sensing, imaging, and computing. Artilux’s vision is to redefine the interaction between light and intelligence, creating a seamlessly connected world where photonics and electronics converge to power the next generation of sensing, communication, and computing. For more information, visit www.artilux.ai.

AION UT Achieves Strong Global Launch, Driving Robust Sales Across Key Markets and Earning Multiple International Honors

GUANGZHOU, China, April 15, 2026 /PRNewswire/ — Since its 2025 global debut, the AION UT has rapidly gained traction across Southeast Asia, South America, and Europe. In Q1, it delivered over 2,400 units in Thailand—securing a Top 3 position in the electric hatchback segment and surpassing 2,500 orders at the Bangkok Motor Show. Indonesia saw deliveries exceed 800 units with a monthly peak over 300, earning a Top 2 segment ranking. In Uruguay, 110 units were delivered within 17 days of launch, claiming the No.1 spot in the electric hatchback C-segment. Colombia recorded a single‑month registration high of 96 units, taking the segment crown. Singapore maintained a monthly average of over 30 orders to lead the segment, while Mexico surpassed 700 quarterly deliveries to hold a firm Top 3 position. Hong Kong SAR accumulated over 1,000 orders, topping the hatchback segment for two consecutive months. In Australia, the model secured 600 pre‑orders within its first month, demonstrating strong market appeal.

On the global stage, the AION UT has swept up prestigious awards with its exceptional product quality. It has won major accolades including “Best Value EV” at Bangkok International Motor Show, “Best Compact EV” at Mexico’s TOP 26 AUTO SHOW, “Best 5-Door Electric Hatchback” at Thailand CAR OF THE YEAR 2026, and “Best Mid-Size Electric Hatchback” at Indonesia International Auto Show. Global media have echoed the acclaim—leading outlets such as Germany’s electrive and Australia’s Drive‑Electric have lauded the vehicle for its exceptional urban driving dynamics, class-leading space and outstanding range‑to‑price ratio.

Underpinning this momentum is robust technology: styling by Milan Design Center, a 2,750mm wheelbase delivering segment‑leading interior room, Magazine Battery 2.0 safety with zero thermal runaway incidents, 24‑minute fast charging and V2L functionality for urban and outdoor versatility.

AION UT’s global momentum confirms GAC’s evolution from product export to a full‑fledged ecosystem globalization.

For further information about GAC, please visit: https://www.gacgroup.com/en or follow us on social.

Clicklinks | 14-Day Candidate Antibody Discovery – Sanyou AI-STAL 2.0 Defines the Era of Ultimate Speed in Drug Molecule Discovery

SHANGHAI, April 15, 2026 /PRNewswire/ — 

01 Introduction

In the race of innovative drug R&D, whether for antibodies, peptides, or novel binding proteins, the efficiency of early-stage molecule discovery is always the key factor determining project success or failure. However, traditional molecular discovery processes have long suffered from an imbalance between”time line” and “quality”. Conventional screening methods often take months, making it difficult to respond to rapidly changing market competition. Moreover, when faced with ultra-large libraries, the throughput of wet-lab screening is disconnected from digital evaluation systems, causing a large number of potential drug molecules with high affinity and high specificity to be buried in massive data. Furthermore, insufficient prediction of expression levels in eukaryotic systems and delayed developability assessment of early molecules have become common industry pain points restricting R&D success rates.

To address the above challenges, Sanyou Bio, leveraging itsIntelligent Core, officially launches the “14-Day Lead Molecule Discovery Workflow” applicable to various molecule types including antibodies, peptides, and binding proteins. This workflow integrates AI-guided Digital Panning, intelligent sequence-structure analysis, and eukaryotic optimized production systems, compressing the entire process from library panning to core molecule validation into 14 days. The significance of this solution lies in breaking the linear rhythm of traditional biological experiments. Through a deep closed loop of “in silico and in vitro” experiments, it not only locks high-quality candidate molecules in an extremely short time but also mitigates developability risks at an early stage, providing global biopharmaceutical partners with an ultimate acceleration solution from sequence to validated molecule.

02 Platform Background

The core capability of AI-STAL 2.0 is rooted in its vast and precise molecular repository. This repository is not a simple collection from a single source, but a three-dimensional molecular discovery ecosystem composed of multiple ultra-trillion-scale, highly specialized sub-libraries, specifically including: Super Trillion Fully Human Antibody Library, Super Trillion Common Light Chain Antibody Library, Super Trillion 2C-Type Single-Domain Antibody Library, Super Trillion 4C-Type Single-Domain Antibody Library, Super Trillion Cyclic Peptide Library, Super Trillion Novel Targeted Protein Library, as well as Magnetic Array Mouse Immune Antibody Library, Magnetic Array Alpaca Immune Antibody Library, Magnetic Array Rabbit Immune Antibody Library, and Magnetic Array Canine Immune Antibody Library.

These ten sub-libraries each have unique characteristics and are widely applicable to therapeutics, diagnostics, detection, and research. It is precisely the synergistic exploration engine formed by these ten sub-libraries that endows AI-STAL 2.0 with the core capability to precisely identify high-potential lead molecules from trillion-level diversity within 14 days, providing the most robust and abundant molecular starting point for breakthrough biologic discovery. To date, the AI-STAL 2.0 platform, relying on this molecular library system, has completed over 1,300 molecule discovery projects, successfully advanced hundreds of PCC projects, with more than ten of them having entered the clinical stage.

03 Platform Advantages

AI-STAL 2.0, through the sequential operation of four intelligent workstations (Station 1 to Station 4), compresses the innovation discovery and validation cycle to just 14 days. The entire process begins with AI-guided activity screening and digital panning, proceeds through intelligent sequence-to-structure mapping and solubility prediction, then enters eukaryotic expression, and finally completes functional validation on Day 14. This workflow not only achieves a full-chain closed loop from molecule generation to validation but also significantly improves the quality and developability of candidate molecules.

Advantage 1: AI-guided Activity Screening for Unbiased Rapid Primary Screening

Traditional phage display panning relies on physical selection, often suffering from limited library coverage and biased screening conditions. AI-STAL 2.0 completely changes this model through AI-guided activity screening. The platform utilizes intelligent algorithms to perform virtual screening on super trillion antibody libraries, rapidly identifying promising core molecules from massive sequences. At the same time, it integrates solubility prediction and real-time affinity and binding validation, eliminating molecules that are difficult to express or prone to aggregation at an early screening stage, thereby significantly increasing the success rate of subsequent experiments and laying a high-quality foundation for the entire discovery process.

Advantage 2: AI Sequence-Structure Analysis for In-Depth Molecular Spatial Configuration

AI-STAL 2.0 demonstrates powerful enabling capabilities in the field of structural biology. Through “intelligent sequence-to-structure mapping” technology, the platform can convert selected amino acid sequences into three-dimensional structural models in an extremely short time. For molecules such as peptides and single-domain antibodies whose biological function is highly dependent on correct spatial folding and conformation, this step not only predicts their tertiary structure but may also involve binding epitope analysis. This helps R&D teams gain deep insights into the interaction mode between the molecule and the target at an early stage, thereby more accurately guiding subsequent optimization directions and avoiding wasting resources on ineffective molecules.

Advantage 3: AI-Optimized Production and Eukaryotic Expression Validation Ensuring Molecule Developability

The AI-STAL 2.0 workflow closely integrates computational design with experimental validation. This stage uses AI-optimized production pathways to design optimal expression and preparation schemes for each candidate molecule, followed by validation using eukaryotic expression systems. Compared to prokaryotic systems, eukaryotic expression more accurately reproduces complex post-translational modifications (such as glycosylation, etc.) of molecules, which is crucial for the activity of complex molecule types like IgG antibodies and binding proteins. Through this step, AI-STAL 2.0 ensures that the delivered molecules not only perform excellently in computational models but also possess good developability and biological activity in actual expression.

Advantage 4: Candidate Molecule Delivery Ready – Complete Closed Loop from Design to Validation in 14 Days

The AI-STAL 2.0 workflow is not just about generating molecular sequences; it provides a complete “validation and delivery” solution. From AI virtual screening on Day 1 to candidate molecules ready for downstream development on Day 14, AI-STAL 2.0 achieves a fully automated and intelligent closed loop for the early drug discovery phase, compressing the traditional multi-month cycle to just two weeks. On Day 14, the R&D team receives not a simple report, but high-quality candidate molecules that have undergone real affinity validation, structural mapping confirmation, and eukaryotic expression optimization, empowering innovative drug pipelines with unprecedented speed.

04 Platform Case Studies

Protein-Level Activity Analysis

Most antibody candidate molecules obtained through AI-STAL 2.0 screening exhibit good protein-level binding activity. Figure 4 shows the affinity measurement results of candidate antibodies binding to antigens analyzed by ELISA, where all candidate antibodies showed binding to the antigen.

Cell-Level Activity Analysis

Most antibody candidate molecules obtained through AI-STAL 2.0 screening exhibit good cell-level binding activity. Figure 5 shows the affinity measurement results of candidate antibodies binding to antigens analyzed by FACS, where all candidate antibodies showed binding to the overexpressing cell line.

05 Summary and Outlook

Sanyou Bio’s 14-Day Candidate Antibody Discovery Workflow is a deep practice of the “intelligent R&D” concept, marking the entry of Sanyou Bio’s drug R&D into a new stage of “high speed, high throughput, and high certainty”. From AI-assisted digital screening on Days 1-6, to precise “sequence-structure” intelligent mapping on Day 7, and then to eukaryotic expression validation and bioactivity assays such as ELISA on Days 8-14, every key node reflects a data-driven closed-loop logic. This workflow demonstrates strong universality, perfectly covering antibodies, peptides, and binding proteins. This data-driven, AI-assisted decision-making closed-loop system not only ensures the activity of delivered molecules but also lays a solid molecular quality foundation for subsequent preclinical development.

Looking ahead, Sanyou Bio will continue to delve deeply into the intersection of AI and biotechnology, committed to transforming technological advantages into productive forces that drive industry change. With the continuous evolution of the AI-STAL 2.0 platform, we plan to achieve a fully automated closed loop for R&D processes by 2026 and strive to complete the full integration of AI tools into the “Agent” R&D model within the year. Sanyou Bio is willing to empower global drug R&D with this ultimate R&D efficiency, leveraging more forward-looking technology layouts and more efficient R&D platforms, to accelerate more innovative drugs towards the clinic with the support of AI, benefiting patients worldwide.

About Sanyou

Sanyou Biopharmaceuticals is a high-tech biopharmaceutical company driven by the mission of “making innovative biologics R&D easy for clients worldwide”. The company is committed to fundamentally addressing the key challenges at the source of innovative drug development.

Powered by its AI-STAL and supported by an integrated wet-lab/dry-lab R&D platform, Sanyou provides comprehensive, one-stop solutions for innovative drug discovery, with a particular focus on molecular discovery and selection.

Sanyou Bio has been dedicated to developing a world-class innovative biological drug R&D hub and to working collaboratively with partners worldwide to accelerate the development of innovative therapeutics.

Headquartered in Shanghai, China, Sanyou has established global business centers across Asia, North America, and Europe, forming an international business network. The company currently operates and has planned over 20,000 square meters of R&D and GMP facilities.

Sanyou has established strong collaborations with more than 2,000 pharmaceutical and biotech companies worldwide, empowering over 1,200 new drug discovery and development projects. It has completed more than 50 collaboration projects, over 10 of which have advanced to IND approval and clinical development stages.

The company has filed over 170 invention patents, with more than 30 granted. It has also obtained over 10 national and international qualifications and system certifications, including National High-Tech Enterprise, Shanghai “Specialized and Innovative” Enterprise, ISO9001, and ISO27001.

Axtria Acquires Conexus Solutions, Uniting Agentic AI and CRM Mastery to Redefine Life Sciences Commercialization

BERKELEY HEIGHTS, N.J., April 15, 2026 /PRNewswire/ — Axtria Inc., a global leader in AI-first data analytics solutions for the life sciences industry, today announced the acquisition of Conexus Solutions, a premier life sciences technology and managed services partner specializing in CRM transformation across the Veeva and Salesforce ecosystems.

With this acquisition, Axtria makes a decisive entry into end-to-end CRM, combining one of the industry’s most trusted CRM practices with its market-leading agentic AI platform. The result is something life sciences commercialization has never had: a unified intelligence layer connecting systems of engagement with systems of intelligence, from data foundation to field execution to patient impact.

“This is not incremental. This is the convergence the industry has been waiting for.”

The Market Moment

Life sciences commercial, quality and R&D operations are undergoing a structural transformation. Patent cliffs are compressing revenue timelines. Specialty and cell-and-gene therapies demand hyper-targeted engagement across smaller, harder-to-reach populations. Payers are raising the bar on outcomes-based evidence. And at the center of every commercial, quality and R&D business sits CRM, the system of record for every customer interaction, yet still operating as a transactional layer, disconnected from the intelligence that should be powering it.

This acquisition bridges that gap. Conexus brings the CRM execution layer, deep Veeva and Salesforce expertise, and client trust that Axtria’s AI platform needs to deliver transformation, not in concept, but in production, at scale, inside the systems that commercial, quality and R&D operation teams rely on every day.

Axtria has been building for this moment. Years before the industry reached consensus on AI-driven commercialization, Axtria was investing in an agentic AI platform purpose-built for life sciences and engineered to move from insight to orchestration. This acquisition is the strategic culmination of that vision, executed at precisely the right time.

The companies that move first to unify intelligence and engagement will define the next era. Axtria is moving first.

A Highly Complementary Strategic Combination

Axtria brings its industry-leading agentic AI platform including Axtria SalesIQ™, Axtria CustomerIQ™, Axtria MarketingIQ™, and Axtria DataMAx™, delivering AI-native sales planning, commercial data optimization, next-best-action intelligence, and enterprise-grade orchestration.

Conexus Solutions brings domain expertise within commercial, quality and R&D operations refined over years of CRM transformation, a scaled and certified talent base, proven advisory capabilities, and deep partnerships across the Veeva and Salesforce ecosystems recognized by these two CRM players. Conexus is a premier services partner with Vault CRM expertise.

The result: an end-to-end capability across the life sciences commercial and customer engagement stack, powered by AI, grounded in domain expertise, and designed to deliver measurable outcomes.

From the Leadership

“This acquisition is a highly strategic step in Axtria’s journey to build the most comprehensive AI-driven commercial platform for life sciences. Conexus brings exceptional CRM expertise, deep customer relationships, and a talented team that complement our capabilities perfectly. Together, we are uniquely positioned to bridge systems of engagement with systems of intelligence, delivering integrated, outcome-driven solutions to our clients,” Jassi Chadha, President and CEO, Axtria.

“Joining Axtria is an exciting next step for Conexus. Our shared commitment to customer success, innovation, and life sciences expertise makes this a natural and powerful combination. Our clients will continue to receive the same trusted service while gaining access to Axtria’s broader capabilities over time,” Akshay Kapadia, Founder and CEO, Conexus Solutions.

Built on Trust. Built to Last.

Clients of both organizations should expect the same trusted partners, the same rigorous delivery, and the same commitment to success now backed by the combined depth of two organizations united by a single standard: whether it moves the needle for patients.

What Conexus has built with its clients was built on relationships, responsiveness, and a culture that treats every engagement as a partnership. That culture is not something to be absorbed. It is the reason this acquisition exists, and it is what Axtria intends to protect, invest in, and amplify.

Why This Changes the Game

For too long, the life sciences technology landscape has asked commercial, quality and R&D teams to stitch together fragmented solutions: one vendor for data, another for analytics, another for CRM, another for field intelligence. The result is complexity without coherence and a persistent gap between strategic insight and frontline execution.

Axtria and Conexus intend to close that gap not by assembling loosely connected tools, but by building an integrated, AI-native operating model for life sciences commercialization.

The future belongs to organizations that turn intelligence into action at the speed their patients demand. That future starts now.

About Axtria

Axtria helps life sciences companies harness the potential of data science and software to improve patient outcomes by connecting the right therapies to the right patients at the right time. A leading global provider of award-winning cloud software and data analytics, Axtria delivers proven solutions that help pharmaceutical, medical device, and diagnostics companies complete their journey from data to insights to action. As a participant in the United Nations Global Compact, Axtria is committed to aligning strategies and operations with universal principles on human rights, labor, environment, and anti-corruption. For more information, visit www.axtria.com.

About Conexus Solutions

Conexus Solutions, is a life sciences technology and managed services partner helping commercial, quality and R&D teams simplify complexity, reduce risk, and operate more efficiently. With deep industry expertise and flexible, scalable delivery across Veeva, Salesforce, AI, analytics, and operational support, Conexus enables life sciences companies to accelerate growth, strengthen engagement, and focus on innovation and patient outcomes.

 

Datasea Inc. (NASDAQ: DTSS) Advances International Commercialization of Acoustic + AI Wellness Care Robots and Prepares U.S. Launch of Acoustic Disinfection Products

Based on preliminary internal assessments, these initiatives may contribute approximately $10 million in incremental revenue in the next fiscal year, subject to execution and market conditions

BEIJING, April 15, 2026 /PRNewswire/ — Datasea Inc. (NASDAQ: DTSS) (“Datasea” or the “Company”), a technology company specializing in acoustic high-tech innovation and AI-driven multimodal digitalization, today announced continued progress in the international commercialization of its acoustic technology-enabled head-focused health and wellness care robot business, alongside preparations for the U.S. market launch of its acoustic disinfection product line.

Building on previously disclosed developments, Datasea is advancing the commercialization of its wellness care robot solutions across China, broader international markets, and the United States through collaboration with strategic partners. In China, related products and services have been deployed in more than 50 cities across approximately 300 service locations. Internationally, the Company has established market cooperation in multiple Asian markets, including South Korea, Hong Kong SAR, Taiwan region, Singapore, Indonesia, and Malaysia. In the United States, Datasea has initiated early-stage commercial rollout activities, including pilot deployments and customer engagements in Boston, New Jersey, Los Angeles, and Phoenix. These developments reflect the Company’s efforts to establish a scalable commercialization pathway for its acoustic technology-enabled wellness solutions across multiple geographic markets.

In parallel, Datasea announced that its acoustic disinfection products, including its Smart Air Sterilizer, have completed overseas testing and certification procedures and are now preparing for commercial launch in the United States. As disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2025, the Company plans to advance U.S. market sales of these products through Datasea Acoustics LLC, its wholly owned Delaware subsidiary.

The Smart Air Sterilizer is designed for air disinfection and environmental hygiene applications, supporting pathogen reduction and improved air quality in both household and commercial settings. The product is intended for use across a range of environments, including homes, healthcare-related settings, hotels, airports, schools, and other public spaces. The Company believes that the combination of its acoustic technology capabilities, smart-environment application potential, and adaptability across multiple usage scenarios may provide a differentiated value proposition as it prepares for U.S. market entry.

The Company’s commercialization approach is centered on proprietary products and intellectual property, acoustic technology-enabled solutions, and scalable deployment across healthcare, wellness, beauty service, and consumer care environments. Datasea believes that, as market access and customer adoption continue to expand, this model may support multiple revenue streams, including hardware product sales, technical service fees, solution integration revenues, and recurring service-based revenues associated with deployed terminals and operating scenarios. The Company believes that the parallel advancement of its wellness care robot business and acoustic disinfection product line further demonstrates the expanding commercial applicability of its acoustic technology platform, and that these two product and solution lines may serve as complementary components of its broader acoustic high-tech commercialization strategy across the United States and international markets.

Based on preliminary internal assessments, the Company believes that, if current commercialization initiatives progress as expected, these businesses may have the potential to contribute up to approximately $10 million in incremental revenue in the next fiscal year. Such estimates are based on current internal expectations and are subject to significant uncertainties, including the pace of market adoption, execution progress, customer demand, channel performance, regulatory considerations, and other factors. There can be no assurance that such results will be achieved.

Ms. Zhixin Liu, Chief Executive Officer of Datasea Inc., commented:

“We believe the continued expansion of our acoustic technology-enabled wellness care robot business across China, international markets, and the United States, together with the planned U.S. launch of our acoustic disinfection products following overseas testing and certification, represents meaningful progress in the commercialization of our acoustic technology platform.

By advancing multiple product and solution lines in parallel, we are establishing a broader commercial foundation for our acoustic high-tech business across healthcare, wellness management, intelligent service, and environmental hygiene applications. We remain focused on disciplined execution and market rollout as we continue to expand our presence across domestic and international markets.

Based on our preliminary internal assessments, we believe these initiatives may create an incremental revenue opportunity of approximately $10 million in the next fiscal year, although actual results will depend on market adoption, execution progress, and overall operating conditions.”

The Company notes that both the expansion of its wellness care robot business and the U.S. commercialization of its acoustic disinfection products remain subject to execution progress, market conditions, and other uncertainties, and there can be no assurance regarding the timing, scale, or financial impact of these initiatives.

For additional information regarding the Company’s financial results and operations, please refer to the Company’s filings with the U.S. Securities and Exchange Commission.

About Datasea Inc.

Datasea Inc. (“Datasea”) is a leading provider of products, services, and solutions for enterprise and retail customers in two innovative industries, acoustic high tech and 5G-AI multimodal digitalization. The Company’s advanced R&D technology serves as the core infrastructure and backbone for its products. Its 5G multimodal digital segment operates on a cloud platform based on AI. Datasea leverages cutting-edge technologies, precision manufacturing, and ultrasonic, infrasound and directional sound technology in its acoustics business to combat viruses and prevent human infections, and it is also developing applications in medical ultrasonic cosmetology. In July 2023, Datasea established a wholly-owned subsidiary, Datasea Acoustics LLC, in Delaware, in a strategic move to enter the U.S. markets and to mark its global expansion plan. For additional information, please visit www.dataseainc.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will”, “expects”, “anticipates”, “future”, “intends”, “plans”, “believes”, “estimates”, “target”, “going forward”, “outlook,” “objective” and similar terms. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and which are beyond Datasea’s control, which may cause Datasea’s actual results, performance or achievements (including the RMB/USD value of its anticipated benefit to Datasea as described herein) to differ materially and in an adverse manner from anticipated results contained or implied in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in Datasea’s filings with the SEC, which are available at www.sec.gov. Datasea does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

Investor and Media Contact: 

Datasea Investor Relations
Email: investorrelations@shuhaixinxi.com 
sunhezhi@shuhaixinxi.com 

Precept Investor Relations LLC

David Rudnick
+1 646-694-8538
david.rudnick@preceptir.com

Tsingke Unveils ‘Zero-Contact’ Gene Synthesis to Safeguard Core Genetic Sequences

BEIJING, April 15, 2026 /PRNewswire/ — As the pace of biotechnology research accelerates, companies are increasingly challenged to balance rapid innovation with the protection of sensitive genetic information. Responding to this trend, Tsingke Biotech today introduced its “Zero-Contact Sequences” system—a fully automated, on-site platform designed to minimize the risk of sequence exposure while offering a practical model for secure and efficient R&D.

Tsingke Gene Factory: Intelligent Gene Synthesis Production Line
Tsingke Gene Factory: Intelligent Gene Synthesis Production Line

Industry Trends: Growing Focus on Sequence Security

Across antibody therapeutics, cell and gene therapies, oligonucleotide drugs, industrial enzymes, and AI-driven molecular design, securing core genetic sequences is now a key factor in both IP protection and staying competitive. Key industry trends include:

  • Complex workflows create multiple points of vulnerability: From design and synthesis to storage, sensitive sequences can be inadvertently exposed.
  • Intellectual property and market positioning are increasingly critical: Even low-probability leaks can have significant implications.
  • Rising pace of innovation challenges data security management: Maintaining strong security without slowing development is becoming a priority for many companies.

The Zero-Contact Approach: Practical Security and Efficiency

Tsingke’s system enhances gene synthesis security in synthetic biology by:

  • On-site, end-to-end processing: All analysis is performed locally, eliminating cloud storage and reducing potential exposure.
  • Untraceable synthesis: Encrypted sequences are read directly by equipment, with operation logs automatically cleared to minimize human intervention.
  • Automated quality control and controlled sample lifecycle: Only pass/fail results are reported, and plasmids or strains can be destroyed under client supervision, with full monitoring.

Forward-Looking Perspective: Shaping the Future of Biotech R&D

Nan Zhang, Global Marketing Manager at Tsingke Biotech, said, “As synthetic biology and biotech R&D evolve, ensuring gene synthesis security and protecting intellectual property are more critical than ever. The Zero-Contact system represents more than a step forward in sequence security—it reflects our forward-looking approach to the future of gene research. Through innovations like this, we aim to offer industry-wide insights and contribute to more secure, efficient, and sustainable R&D practices.”

About Tsingke Biotech

Tsingke Biotech is a leading innovator in synthetic biology, dedicated to building “the world’s great gene factory.” By combining proprietary reagents, consumables, and synthesis equipment with AI-driven molecular manufacturing technologies, Tsingke Biotech delivers efficient, high-quality gene synthesis services supporting industries from biopharma to agriculture, food, and environmental sciences.

Contact: market@tsingke.com.cn

AGIBOT Partners with Cerebrotech to bring robotics solutions to the Philippines

SHANGHAI, April 15, 2026 /PRNewswire/ — AGIBOT today announced a strategic partnership with Cerebrotech Inc., marking its expansion into the Philippines market through a local collaboration.

AGIBOT signs strategic cooperation agreement with Cerebrotech
AGIBOT signs strategic cooperation agreement with Cerebrotech

Based in Metro Manila. Cerebrotech is a technology distribution and solutions provider with experience supporting enterprise clients across the Philippines. Through this partnership, AGIBOT will leverage its robotics platforms to support the adoption of embodied AI technologies in the region.

“Expanding into the Philippines markets marks a major milestone in our Asia Pacific growth,” said Abel Deng, President of Middle East and Asia Pacific region of AGIBOT. “Cerebrotech’s understanding of the local market makes them a strong partner as we explore practical ways to bring robotics into real-world business enviroments.”

“We are excited to work with AGIBOT to introduce advanced automation solutions to enterprises in the Philippines,” said Michael Jones L. Sia, Co-founder of Cerebrotech. “By exploring flexible deployment models, including leasing, we hope to lower adoption barriers and support digital transformation across sectors such as manufacturing and logistics.”

Under the initial phase of collaboration, Cerebrotech will serve as AGIBOT’s first local partner in the Philippines, launching a robot leasing business to make advanced robotics more accessible to local enterprises.

For more information, please visit AGIBOT at AGIBOT.com and follow AGIBOT on:

https://www.facebook.com/AGIBOT.zhiyuan
https://x.com/AGIBOT_zhiyuan
https://www.instagram.com/AGIBOT_
https://www.tiktok.com/@agibot_
https://www.youtube.com/@AGIBOT-robot

About AGIBOT

AGIBOT is dedicated to driving innovation through the integration of AI and robotics, creating world-leading general-purpose embodied robot products and an application ecosystem. Built on the foundation of the robotic body and powered by the fusion of interaction, manipulation, and locomotion intelligence — “1 Robotic Body, 3 Intelligence” — AGIBOT is a leading robotics company in the industry to deliver a complete product portfolio and deploy across all major application scenarios. In March 2026, AGIBOT announced the rollout of its 10,000th robot, marking a major milestone in large-scale production and deployment.

Media Contacts: 

Mr. Jason Liu
AGIBOT
liupeng1@agibot.com